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Tumor suppressor p53 controls cell cycle checkpoints and apoptosis via the transactivation of several genes
that are involved in these processes. The functions of p53 are regulated by a wide variety of proteins, which
interact with it either directly or indirectly. The multifunctional human transcriptional coactivator PC4
interacts with p53 in vivo and in vitro and regulates its function. Here we report the molecular mechanisms of
the PC4-mediated activation of p53 function. PC4 interacts with the DNA binding and C-terminal domains of
p53 through its DNA binding domain, which is essential for the stimulation of p53 DNA binding. Remarkably,
ligation-mediated circularization assays reveal that PC4 induces significant bending in the DNA double helix.
Deletion mutants defective in DNA bending are found to be impaired in activating p53-mediated DNA binding
and apoptosis. Furthermore, acetylation of PC4 enhances, while phosphorylation abolishes, its ability to bend
DNA, activate p53 DNA binding, and, thereby, regulate p53 functions. In conclusion, PC4 activates p53
recruitment to p53-responsive promoters (Bax and p21) in vivo through its interaction with p53 and by
providing bent substrate for p53 recruitment. These results elucidate the general molecular mechanisms of
activation of p53 function, mediated by its coactivators.
p53, a well-known tumor suppressor, maintains genomic in-
tegrity and cellular homeostasis. The tumor suppressor func-
tion of p53 is a contribution of its ability to exert DNA repair,
cell cycle arrest, and apoptosis (11, 21, 31). Under normal
conditions, p53 is a short-lived protein and is maintained at
very low levels; only upon genotoxic insult is p53 stabilized and
activated by several factors. Therefore, the stabilization and
activation of p53 play pivotal roles in modulating p53 function
(2). The cellular functions of p53 depend on its protein levels
(32), posttranslational modifications, and functional interact-
ing partners (24). Posttranslational modifications differentially
regulate p53 function, depending on the types and sites of
modification. For example, phosphorylation of residue S15 in
p53 releases MDM2 from p53 and enhances the interaction
with acetyltransferases p300/CBP (39). p300/CBP-mediated
acetylation of residue K373 in p53 leads to apoptosis, whereas
acetylation of residue K320 by PCAF leads to cell cycle arrest
(23). Acetylation of p53 is also reported to augment its DNA
binding ability (14). While ubiquitination of p53 leads to its
proteosomal degradation (7), methylation by Set9 restricts it to
the nucleus and stabilizes the protein (8).
Several p53-interacting proteins regulate its stability and
function either positively or negatively. MDM2, COP1, and
PirH1 act as negative regulators of p53 by promoting its ubiq-
uitination (10, 15, 25, 28, 34). Proteins p19ARF and HAUSP
positively regulate p53 function by preventing MDM2-p53 in-
teraction and promoting p53 deubiquitination, respectively
(29, 37). Overexpression of HES1, HEY1, TFAP4, and OSR1
activate p53 function by repressing MDM2 transcription (16).
TAF31 and TAF70 activate p53-dependent transcription by
recruiting basal transcription machinery (5, 6). Furthermore,
histone methyltransferases PRMT1 and CARM1 physically in-
teract with p53 and cooperatively activate p53-responsive gene
expression in association with acetyltransferases p300/CBP (1).
A group of p53-interacting proteins, including HMGB1,
PC4, and the ASPP family of proteins, enhance the sequence-
specific DNA binding ability and transactivation functions of
p53 (4, 17, 38). HMGB1, a nuclear protein, activates p53 bind-
ing to its cognate sites, as well as p53-dependent transcription,
by providing a bent DNA for p53 recruitment (17, 30). The
multifunctional human transcriptional coactivator PC4, a
highly abundant nuclear protein, activates activator-dependent
DNA transcription through RNA polymerase II (12). It plays
an important role in transcription, replication, DNA repair,
and normal cellular growth (12, 20, 35, 41). Recently we have
found that PC4 is a chromatin-associated protein and is im-
portant for chromatin organization and cell cycle progression
(9). PC4 is phosphorylated by CKII and acetylated by p300.
While phosphorylation negatively regulates PC4’s coactivator
function and double-stranded DNA (dsDNA) binding ability,
acetylation of PC4 enhances its dsDNA binding ability (13, 26).
Furthermore, phosphorylation of PC4 negatively regulates its
acetylation (26). PC4 can inhibit the AP2 self-repression in a
Ras-transformed cell line, suggesting its role as a putative tu-
mor suppressor (20). PC4 enhances p53 binding to its cognate
sites and, also, the transcription of p53-responsive genes. It
interacts with p53 in vitro and in vivo and activates p53-medi-
ated apoptosis by enhancing the expression of the proapoptotic
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gene Bax (4). However, the mechanism of PC4-mediated acti-
vation of p53 function remains elusive.
The present study investigated the molecular mechanisms of
the PC4-mediated activation of p53 function. We have identi-
fied the p53-interacting region in PC4, which is important for
the activation of p53 DNA binding. Posttranslational modifi-
cations of PC4, such as acetylation, induce its ability to activate
p53 DNA binding, whereas phosphorylation dramatically abol-
ishes the enhancement of p53 DNA binding. Interestingly, we
have found a new activity of PC4, an intrinsic DNA-bending
ability, which is also regulated by posttranslational modifica-
tions. The DNA-bending ability of PC4 significantly contrib-
utes to the activation of p53 recruitment to p53-responsive
promoters in vivo. Presumably PC4, through its interaction
with p53 and its DNA-bending ability, induces the recruitment
of p53 to p53-responsive gene promoters and thereby activates
the physiological functions of p53.
MATERIALS AND METHODS
Plasmid construction. Full-length recombinant PC4 and its truncated mutants
PC4 1-40, PC4 1-62, PC4 1-67, PC4 1-72, PC4 1-77, PC4 1-82, PC4 1-87, PC4
22-127, PC4 40-127, and PC4 62-127 were constructed by PCR amplification of
genes corresponding to amino acids from a PC4 full-length cDNA clone. The
amplified products were cloned into the pET28b vector at the NcoI and XhoI
restriction sites, with a C-terminal His6 tag, for bacterial expression and into
PCDNA 3.1() at the NheI and HindIII restriction sites for mammalian expres-
sion. PC4 point mutants were constructed using a site-directed mutagenesis kit
(Stratagene). PC4 internal deletion mutant PC462-87 was constructed by PCR
amplification of PC4 1-62 and PC4 87-127, with complementary overhangs,
followed by annealing and cloning into the pET28b vector at the NcoI and XhoI
restriction sites, with a C-terminal His6 tag, for bacterial expression. PC462-87
and PC4 point mutants cloned in pET28b were used as templates for PCR
amplification of the same fragment with the NheI and HindIII restriction sites
for cloning into PCDNA 3.1() for mammalian expression.
Purification of proteins. Full-length PC4 and its truncation mutants were
purified by Ni-nitrilotriacetic acid affinity chromatography followed by heparin-
Sepharose affinity chromatography. The proteins, expressed and purified from
bacteria, were analyzed on 15% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) gels with Coomassie staining and confirmed by immu-
noblotting using PC4 antibodies. FLAG-tagged p53 was bacterially expressed
and purified using M2-agarose immunoaffinity chromatography. Glutathione
S-transferase (GST) and GST bound to p53 and its truncation mutants were
expressed and purified using GST affinity chromatography. Recombinant bacu-
lovirus-expressed, full-length, His6-tagged p300 was purified as described else-
where (27).
GST pull-down assay. GST pull-down assays were performed as described
previously (4). Briefly, 1 g of GST, GST-p53, or p53 truncation mutants bound
to GST beads were incubated with 200 ng of recombinant PC4 or its mutants in
a reaction mixture volume of 200 l BC150 (20 mM Tris HCl [pH 7.4], 20%
glycerol, 0.2 mM EDTA, 0.1% NP-40) containing 150 mM KCl at 4°C for 3 h.
The beads were then washed five times with BC150 and were run on 12%
SDS-PAGE gels, followed by immunoblotting with PC4 antibodies.
EMSA. Electrophoretic mobility shift assays (EMSAs) were performed as
described previously (17). A 3-ng amount of a radiolabeled 40-bp oligonucleotide
containing consensus p53 binding sites was incubated in a reaction mixture
volume of 40 l containing 8 l of 5 EMSA buffer (100 mM HEPES [pH 7.9],
125 mM KCl, 0.5 mM EDTA, 50% glycerol, 10 mM MgCl2), 2 l of 60 g/ml
double-stranded poly(dI-dC), and 4 l of bovine serum albumin (1 mg/ml) with
FIG. 1. PC4 domain involved in p53 interaction and activation of p53 DNA binding. (A) Schematic representation of PC4 truncation mutant
constructs. Plus signs indicate strength of p53 interaction, and minus sign indicates no interaction. (B) GST-p53 (panel I), GST-p53 C-terminal
domain (CTD) (panel II), GST-p53 DNA binding domain (DBD) (panel III), and GST (panel IV) proteins were incubated individually with PC4
or one of its truncation mutants, and the interacting proteins were detected by immunoblotting with PC4 antibodies. , anti. (C) Three nanograms
of a -32P-labeled oligonucleotide containing a p53 binding site was incubated with 50 ng of p53 either in the absence of PC4 (lane 2) or with
increasing concentrations of PC4 (lanes 3 and 4), PC4 1-62 (lanes 5 and 6), PC4 1-87 (lanes 7 and 8), PC4 22-127 (lanes 9 and 10), or PC4 62-127
(lanes 11 and 12). Lane 1 contains the -32P-labeled oligonucleotide alone. , present; , absent. (D) Quantitative representation of the effect
of PC4 and its truncation mutants PC4 1-62, PC4 1-87, PC4 22-127, and PC4 62-127 on p53-mediated DNA binding. The levels of induction of
p53-mediated binding are represented on the y axis, with increasing concentrations of PC4 and its truncation mutants on the x axis.
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the proteins as indicated in the figures for 30 min at 30°C. The samples were
analyzed on 5% native PAGE gels containing 0.5 Tris-borate-EDTA (TBE)
buffer and 0.05% NP-40 and electrophoresed at 200 V for 2 h at 4°C. The gels
were dried, and the DNA-protein complexes were visualized with a phosphor-
imager analyzer (Fuji) using Image Gauge software. The quantification of the
level of induction in the formation of DNA-protein complexes was done as an
average of the induction measured in three different independent experiments.
Ligation-mediated circularization assay. The ligation-mediated circulariza-
tion assays were performed as described previously (40), with some minor mod-
ifications. A 1 nM concentration of -32P-labeled 123-bp DNA was incubated
with the proteins indicated in Results in 30 mM Tris-HCl, pH 7.8, 10 mM MgCl2,
10 mM dithiothreitol, and 0.5 mM ATP (1 T4 DNA ligase buffer) in a reaction
mixture volume of 10 l on ice for 20 min. An amount of 0.05 U of T4 DNA
ligase was then added, and the ligation reaction allowed to proceed for 30 min at
30°C, followed by heat inactivation at 65°C for 20 min. Some samples were
treated with 50 U of exonuclease III for 30 min at 37°C. One microliter of stop
solution (10% SDS, 10 g/ml proteinase K) was added to all samples, followed
by deproteination and precipitation of the DNA. The samples were loaded on
5% native PAGE (29:1 acrylamide/N,N-methylene bisacrylamide) gels in 45 mM
Tris base, 45 mM boric acid, 1.25 mM EDTA, pH 8.3 to 8.4 (0.5 TBE buffer)
and the gels were run for 2 h at room temperature. The gels were dried and
analyzed with a phosphorimager (Fuji) using Image Gauge software.
In vitro phosphorylation of PC4. An amount of 1 g of recombinant PC4 was
incubated in phosphorylation buffer (50 mM HEPES-K [pH 7.6], 125 mM
NaCl, 10 mM MgCl2, 6% [vol/vol] glycerol, 5 mM dithiothreitol, and 0.5 mM
phenylmethylsulfonyl fluoride) containing 5 mM ATP with 40 mU of rat liver
CKII in a total volume of 20 l at 30°C. For complete phosphorylation, CKII and
ATP were replenished three times in the reaction mixture, at 30-min intervals.
Mock phosphorylation was performed in a similar way but in the absence of
ATP. The reaction mixtures were then dialyzed against BC100 (20 mM Tris HCl
[pH 7.4], 20% glycerol, 0.2 mM EDTA, 0.1% NP-40, 100 mM KCl) and used for
further experiments.
In vitro acetylation of PC4. An amount of 1 g of recombinant PC4 was
incubated in a 30-l final reaction mixture volume consisting of 50 mM Tris-HCl,
pH 8.0, 10% (vol/vol) glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, 0.1 mM EDTA, pH 8.0, 10 mM sodium butyrate, 0.5 l 3.3 Ci/mmol
[3H]acetyl-coenzyme A (acetyl-CoA), and p300 at 30°C. For complete acetyla-
tion, p300 and acetyl-CoA were replenished three times in the reaction mixture,
at 30-min intervals. Mock acetylation was performed in a similar way but in the
absence of acetyl-CoA. The reaction mixtures were then dialyzed against BC100
and used for further experiments. The authenticity of the acetylation was con-
firmed by immunoblotting with anti-acetylated-lysine antibodies. The in vitro
acetylation of p53 was done in a similar way.
Transfection assay. The p53 null human lung carcinoma cell line H1299 was
grown at 37°C, 5% CO2 in Dulbecco’s modified Eagle’s medium supplied with
10% fetal bovine serum (HyClone) and appropriate antibiotics. Cells were
seeded at 1 million cells per 60-mm dish in Dulbecco’s modified Eagle’s medium
without antibiotics and supplemented with 10% fetal bovine serum 24 h before
transfection. DNA was used for transfections in the amounts indicated in the
figure legends, using Lipofectamine according to the manufacturer’s protocol.
An equal amount of DNA was used in all transfections.
Endogenous gene expression assay. H1299 cells were transfected with PC4/
PC4 mutants, p53, or both the mammalian expression constructs. After 24 h of
transfection, total RNA was isolated from the transfected cells using Trizol
reagent (Invitrogen) and cDNA was made using oligo(dT) (28-mer) and M-MLV
reverse transcriptase (Invitrogen). This cDNA was used for real-time PCR anal-
ysis using iQTM SYBR Green supermix (Bio-Rad) with gene-specific primers for
Bax, p21, and Actin.
ChIP. H1299 cells transfected with PC4/PC4 mutants, p53, or both the mam-
malian expression constructs were used for the chromatin immunoprecipitation
assay (ChIP) assay. The ChIP assay was performed as described previously (36).
The pull-downs were done with p53 antibody or control immunoglobulin G
antibody, and the immunoprecipitated samples were deproteinized, ethanol pre-
cipitated, and used for PCR analysis. Real-time PCR analysis was done using the
primers specific to the p53-responsive site in the Bax promoter.
Apoptosis assay. H1299 cells were seeded at 0.6 million cells per 60-mm dish
before 24 h of transfection. The amounts of DNA indicated in the figure legends
were used for transfections, using Lipofectamine according to the manufacturer’s
protocol. After 24 h of transfection, the cells were fixed with 4% formaldehyde
and stained with Hoechst stain. The cells were visualized under a fluorescent
microscope using a blind approach.
RESULTS
PC4-p53 interaction is essential for PC4-mediated activa-
tion of p53 binding to its cognate sites. The multifunctional
transcriptional coactivator PC4 activates p53 function (4).
Given that PC4 interacts with p53 in vitro and in vivo and that
p53 can be regulated by its interacting proteins via different
mechanisms, we investigated the functional significance of the
PC4-p53 interaction in the activation of p53 function. In order
to identify the domain of PC4 that interacts with p53, we
generated a panel of PC4 truncation mutants (Fig. 1A) which
were expressed, purified, and verified by immunoblotting with
PC4 antibodies. These truncation mutant proteins were incu-
bated with affinity-purified GST or GST-p53 proteins for the
interaction studies. As shown in Fig. 1B (panels I and IV),
FIG. 2. Amino acid residues 62 to 87 are essential for p53 interac-
tion and activation of p53 DNA binding. (A) Schematic representation
of PC4 and PC462-87. Plus signs indicate strength of p53 interaction.
(B) GST-p53 or GST protein was incubated individually with PC4 or
PC462-87, and the levels of interaction were determined by immu-
noblotting with PC4 antibodies. , present; , absent; , anti.
(C) EMSAs were performed with 50 ng of p53 in the absence of PC4
(lane 2) or with increasing concentrations of PC4 (lanes 3 to 5) or
PC462-87 (lanes 6 to 8). , present; , absent.
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full-length PC4, PC4 1-87, and PC4 22-127 showed significant
interaction with GST-p53, but not GST alone, whereas PC4
1-62 showed very weak binding and PC4 62-127 did not inter-
act with GST-p53. Similar results were also found when pull-
down assays were performed in the presence of DNase to
exclude the possibility that the PC4-p53 interactions were
merely via DNA (data not shown). PC4 interacts with p53
through its DNA binding domain and C-terminal domain. To
further delineate the PC4 domain that interacts with the p53
DNA binding domain and C-terminal domain, pull-down as-
says were performed with GST-p53 DNA binding domain and
C-terminal domain. The results (Fig. 1B, panels II and III)
showed that the same domain of PC4 is required for its inter-
action with the DNA binding domain and the C-terminal do-
main of p53.
In order to verify the functional correlation of PC4-p53
interaction and the activation of p53 function, we examined the
effects of PC4 truncation mutants on p53 DNA binding.
EMSAs were performed with a 40-bp GADD45 promoter con-
taining p53-responsive elements. FLAG-p53, expressed and
purified in bacteria, formed a sequence-specific complex, and
as expected, the addition of full-length PC4 enhanced p53-
mediated DNA binding in a dose-dependent manner (Fig. 1C,
lane 2 versus lanes 3 and 4). PC4 truncations PC4 1-87 and PC4
22-127, which showed strong interaction with p53, significantly
enhanced p53 DNA binding (lane 2 versus lanes 7 and 8 and
lanes 9 and 10). In agreement with the results of the interaction
studies, PC4 1-62, which showed very weak interaction, acti-
vated p53 DNA binding minimally (lane 2 versus lanes 5 and
6), whereas PC4 62-127, which failed to interact with p53,
could not affect p53 DNA binding (lane 2 versus lanes 11 and
12). However, at a higher concentration, PC4 62-127 activated
p53 DNA binding (data not shown). In order to quantify the
effects of PC4 truncation mutants on p53 DNA binding,
EMSAs were carried out with increasing concentrations of
PC4 or its truncation mutants in the presence of p53, and the
induction of p53 DNA binding (n-fold) was plotted (Fig. 1D).
The results showed that at a given concentration (0.54 M),
PC4 1-62 and PC4 62-127 were able to enhance p53 DNA
binding 2-fold, whereas PC4, PC4 1-87, and PC4 22-127 en-
hanced p53 DNA binding 8-, 11.5-, and 10-fold, respectively.
The above results suggest that amino acids 62 to 87 of PC4
that are involved in the PC4-p53 interaction could be respon-
sible for the activation of p53 DNA binding. To further sub-
stantiate this, an internal deletion mutant (PC462-87) was
made (Fig. 2A). As expected, PC462-87 showed a weak in-
teraction with p53 (Fig. 2B, lane 1 versus lane 2), and conse-
quently, no significant increase in p53 DNA binding was de-
tected (Fig. 2C, lane 2 versus lanes 3 to 5 and 6 to 8). Based on
these data, a series of truncation mutants, PC4 1-67, PC4 1-72,
PC4 1-77, and PC4 1-82 (Fig. 3A), covering the region of
amino acid residues 62 to 87 were constructed to find out the
precise amino acid stretch responsible for enhancing p53 DNA
binding. These truncation mutants were expressed and purified
using affinity chromatography and confirmed by immunoblot-
ting with PC4 antibodies. Pull-down assays revealed that PC4
1-67 interacts with p53 very weakly, but the other truncation
mutants showed similar strengths of interaction with p53 (Fig.
3B, panel I). Consistent with the interaction data, DNA bind-
ing assays with these truncation mutants also revealed that PC4
1-67 could enhance p53 DNA binding only very weakly (Fig.
3C, lane 2 versus lanes 5 and 6), whereas the other truncation
mutants, PC4 1-72, PC4 1-77, and PC4 1-82, could enhance p53
DNA binding as efficiently as full-length PC4 (lane 2 versus
lanes 3 and 4, 7 and 8, 9 and 10, and 11 and 12). The results of
the quantification of the effect of PC4 and its truncation mu-
FIG. 3. A critical stretch of 5 amino acids involved in PC4-mediated activation of p53 function. (A) Schematic representation of PC4 and PC4
domains 1 to 67, 1 to 72, 1 to 77, and 1 to 82. Plus signs indicate strength of p53 interaction. (B) GST-p53 or GST proteins were incubated
individually with PC4 1-67, PC4 1-72, PC4 1-77, or PC4 1-82, and the interactions were monitored by immunoblotting with PC4 antibodies. , anti.
(C) EMSAs were performed with 50 ng of p53 in the absence of PC4 (lane 2) or with increasing concentrations of PC4 (lanes 3 and 4), PC4 1-67
(lanes 5 and 6), PC4 1-72 (lanes 7 and 8), PC4 1-77 (lanes 9 and 10), or PC4 1-82 (lanes 11 and 12). , present; , absent. (D) Quantitative
representation of effect of PC4 and its truncation mutants 1-67, 1-72, 1-77, and 1-82 on p53-mediated DNA binding. The levels of induction of
p53-mediated binding are represented on the y axis, and the increasing concentrations of PC4 or its truncation mutants on the x axis.
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tants PC4 1-67, PC4 1-72, PC4 1-77, and PC4 1-82 on p53-
mediated DNA binding are represented in Fig. 3D. The results
showed that at a concentration of 0.36 M, PC4 1-67 could
activate p53 binding 1.5-fold, whereas the other truncation
mutants, PC4 1-72, PC4 1-77, and PC4 1-82, could enhance p53
binding 3- to 4-fold, suggesting that amino acids 68 to 72 are
important for this function (Fig. 4A). To further elucidate the
amino acid residues responsible for the activation of p53 DNA
binding, K68 and M69 of PC4 were mutated to alanine (Fig.
4B), and the results showed that these point mutations in PC4
affect neither its binding with p53 (Fig. 4C, panel I) nor its
ability to activate p53 function (Fig. 4E, lane 2 versus lanes 3
and 4 and lanes 9 and 10). However, PC4 R70AY71A, where
R70 and Y71 of PC4 were mutated to alanine (Fig. 4B),
showed a dramatic reduction in p53 interaction (Fig. 4C, panel
I) and was not potent enough to activate p53 DNA binding,
suggesting the importance of these amino acids in the PC4-
mediated activation of p53 function (Fig. 4E, lane 2 versus
lanes 3 and 4 and lanes 11 and 12). Further evidence that the
PC4-p53 interaction is responsible for the PC4-mediated acti-
vation of p53 DNA binding comes from the PC4 truncation
mutants PC4 1-40 and PC4 40-127 (Fig. 4B). PC4 1-40 did not
show any interaction with p53 (Fig. 4D, panel I) and also could
not enhance p53-mediated DNA binding (Fig. 4E, lane 2 ver-
sus lanes 3 and 4 and lanes 5 and 6), whereas PC4 40-127
interacted with p53 (Fig. 4D, panel I) and activated p53 DNA
binding similarly to native PC4 (Fig. 4E, lane 2 versus lanes 3
and 4 and lanes 7 and 8). In the absence of p53, none of the
truncation mutants of PC4 formed any sequence-specific
DNA-protein complex (data not shown).
Glutaraldehyde cross-linking experiments and the crystal
structure of the PC4 C-terminal domain gave us a clue that
PC4 may exist as a dimer and a tetramer in vitro (data not
shown). Furthermore, the results of immuno-pull-down of
FLAG-PC4 from the transfected whole-cell lysates revealed
that PC4 exists as a multimer in vivo (data not shown). Taken
together, these results suggest that possibly a dimer of PC4
interacts with the DNA binding domain and C-terminal do-
main of p53 through the stretch of amino acid residues 62 to
87, and the interaction is essential to enhance the DNA bind-
ing of p53. Presumably, a dimer of PC4 interacts with a mono-
mer of p53, forming a complex containing eight molecules of
PC4 with a tetramer of p53.
Posttranslational modifications of PC4 regulate its ability to
activate p53 binding to its cognate sites. The transcriptional
coactivator PC4 undergoes posttranslational modifications like
acetylation and phosphorylation (13, 26). Phosphorylation of
PC4 abolishes its coactivator function, its ability to interact
with dsDNA and different transcription factors, whereas acety-
lation is known to enhance its dsDNA binding ability (13, 26).
In order to examine the effects of posttranslational modifica-
tions of PC4 on its ability to activate p53 function, PC4 was
phosphorylated and acetylated by CKII and p300, respectively,
in vitro. Upon complete phosphorylation, PC4 showed dis-
tinctly slower mobility than native PC4 on a 15% SDS-PAGE
gel (Fig. 5A, panel I). The level of acetylation was determined
FIG. 4. R70 and Y71 of PC4 are important for PC4-mediated activation of p53 function. (A) Schematic representation of 5 amino acids
important for PC4-mediated activation of p53 function. (B) Schematic representation of PC4, PC4 R70AY71A, PC4 K68AM69A, PC4 1-40, and
PC4 40-127. (C) GST-p53 or GST proteins were incubated individually with PC4, PC4 R70AY71A, or PC4 K68AM69A, and the interactions were
monitored by immunoblotting with PC4 antibodies. , anti. (D) GST-p53 or GST proteins were incubated individually with PC4, PC4 1-40, or PC4
40-127, and the interactions were monitored by immunoblotting with PC4 antibodies. (E) EMSAs were performed with 50 ng of p53 in the absence
of PC4 (lane 2) or with increasing concentrations of PC4 (lanes 3 and 4), PC4 1-40 (lanes 5 and 6), PC4 40-127 (lanes 7 and 8), PC4 K68AM69A
(lanes 9 and 10), or PC4 R70AY71A (lanes 11 and 12). , present; , absent.
VOL. 27, 2007 MECHANISMS OF ACTIVATION OF p53 FUNCTION BY PC4 7607
by mass spectrometric analysis of acetylated PC4 and native
PC4. The absence of the mass spectrum peak that corresponds
to the native protein upon the acetylation of PC4 assured the
complete acetylation of the protein at the six possible sites
(data not shown). Pull-down assays with GST-p53 and unmod-
ified/modified forms of PC4 showed that phosphorylation of
PC4 completely abolishes its ability to interact with p53 (Fig.
5A, panel III, lane 1 versus lane 2), whereas acetylation of PC4
did not show any detectable effect on the PC4-p53 interaction
(Fig. 6A, panel IV, lane 1 versus lane 2). Further emphasizing
the importance of the PC4-p53 interaction, phosphorylated
PC4 lost the ability to activate p53 DNA binding but mock-
phosphorylated PC4 could activate p53 DNA binding to a level
similar to that of unmodified PC4 (Fig. 5B, lane 2 versus lanes
3 to 5, 6 to 8, and 9 to 11). Although acetylated PC4 showed a
strength of interaction with p53 similar to that of the native
form, it could activate p53 DNA binding more potently than
the unmodified PC4 (Fig. 6B, lane 2 versus lanes 3 to 5, 6 to 8,
and 9 to 11). In order to confirm that acetylation of PC4, but
not p53 acetylation, is responsible for the activation of p53
DNA binding, EMSAs were performed in the presence of
acetylated PC4, p53, and curcumin (a well-known specific in-
hibitor of p300 acetyltransferase activity) (3). Curcumin as
such does not affect p53-mediated DNA binding (data not
shown) but rather inhibits p53 acetylation by p300 (3). The
results showed that the presence of curcumin did not inhibit
the activation of p53 DNA binding in the presence of acety-
lated PC4 and p53, suggesting the role of PC4 acetylation in
this function (Fig. 6D, lane 6 versus lane 7). The results of
quantification of the effects of modified/unmodified forms of
PC4 on p53 DNA binding (Fig. 5C and 6C) revealed that at a
given concentration (0.18 M), unmodified PC4, acetylated
PC4, and phosphorylated PC4 could activate p53 binding 2.3-,
8-, and 1.3-fold, respectively. Acetylation of p53 enhances its
sequence-specific DNA binding ability (Fig. 6E, lane 2 versus
lane 3). Interestingly, when we investigated the effect of PC4
on DNA binding by acetylated p53, we found that PC4 could
enhance acetylated-p53-mediated DNA binding better than
native p53 DNA binding (Fig. 6F, lane 2 versus lanes 3 and 4
and lane 5 versus lanes 6 and 7). As expected, phosphorylated
PC4 had no effect on the DNA binding ability of acetylated
p53. However, acetylated PC4 showed a marginal enhance-
ment of acetylated-p53-mediated DNA binding over the level
with native PC4 (data not shown). Taken together, the acety-
lation of PC4 that has hardly any effect on PC4-p53 interaction
could efficiently activate p53 DNA binding, suggesting multiple
mechanisms of the PC4-mediated activation of p53 function
apart from protein-protein interaction.
PC4 is a DNA-bending protein. p53 binds more efficiently to
the bent DNA surface than to linear DNA (30, 33). Our data
suggest that the protein-protein interaction may not be the
only molecular event responsible for the activation of p53
DNA binding by PC4. We presumed that PC4 may also induce
DNA bending to perform this function. The effect of PC4
on DNA structure was addressed by performing ligation-me-
diated circularization assays, which have been extensively used
to determine the DNA-bending ability of proteins. This assay
works on the principle that any dsDNA of less than 150 bp in
length will not circularize itself in the presence of ligase be-
cause of inherent limitations in the flexibility of DNA. There-
fore, circularization is seen only in the presence of a DNA-
bending protein. In order to verify the DNA-bending
properties of PC4, we have performed these assays with a
123-bp -32P-labeled oligonucleotide. A 1 nM concentration of
the oligonucleotide was incubated with different concentra-
tions of PC4 in ice, and the ligation reactions were performed
by the addition of T4 DNA ligase. After the ligation reaction,
exonuclease III treatment was done to verify the circulariza-
tion of the DNA (Fig. 7A, lane 8). As shown in Fig. 7A,
increasing the concentration of PC4 could result in the forma-
tion of circle monomer and circle dimer in a dose-dependent
manner, whereas ligase alone could not form any circles (lane
FIG. 5. Phosphorylation of PC4 abolishes its ability to activate p53
function. (A) PC4 was phosphorylated in vitro by CKII as described in
Materials and Methods, and the native PC4 and phosphorylated PC4
were analyzed on a 15% SDS-PAGE gel (panel I). GST-p53 protein
was incubated with PC4 or phosphorylated PC4 (panel II), and the
interacting proteins were monitored by immunoblotting with PC4 an-
tibodies (panel III). , anti. (B) PC4 was phosphorylated in vitro by
CKII, using ATP as the substrate, and mock phosphorylation was done
in the absence of ATP. EMSA was performed with 50 ng of p53 either
in the absence of PC4 (lane 2) or with increasing concentrations of
PC4 (lanes 3 to 5), mock-phosphorylated PC4 (lanes 6 to 8), or phos-
phorylated PC4 (lanes 9 to 11). , present; , absent. (C) The levels
of induction of p53-mediated binding are represented on the y axis,
with increasing concentrations of PC4 or its phosphorylated form on
the x axis. P, phosphorylated.
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2 versus lanes 3 to 8). To further analyze the domain of PC4
responsible for DNA bending, we performed ligation-medi-
ated circularization assays with PC4 truncation mutants, and
the results showed that, except for PC4 1-62, all of the trun-
cation mutants could efficiently bend the DNA (Fig. 7B, lanes
6, 10, 14, and 18). Significantly, PC4 62-127, which did not
interact with p53 but could activate p53 DNA binding at higher
concentrations, efficiently bent the DNA. However, PC462-
87, which showed weak interaction with p53, could not bend
the DNA (Fig. 7C, lane 6). Taken together, these results elu-
cidate the intrinsic DNA-bending property of PC4 which is one
of the important functional components in its enhancement of
p53 function.
Posttranslational modifications of PC4 regulate its DNA-
bending ability. Acetylation of PC4 enhances its ability to
activate p53 DNA binding; however, acetylation of PC4 does
not alter its ability to interact with p53. Presumably, this post-
translational modification might have a different mechanism to
activate p53 function, which could be the regulation of PC4-
mediated DNA bending. To address this possibility, we carried
out ligation-mediated circularization assays with in vitro-acety-
lated PC4. The results showed that, indeed, acetylated PC4
could bend DNA and form circles in the presence of ligase
much more efficiently than the unmodified form (Fig. 8A, lanes
3 to 6 versus lanes 7 to 10). In contrast, in vitro-phosphorylated
PC4 could not bend DNA, while unmodified PC4 could effi-
ciently bend the DNA (Fig. 8B, lanes 3 to 6 versus lanes 7 to
10). These data clearly establish the role of PC4 acetylation as
an inducing factor for DNA bending and, thereby, the activa-
tion of p53 function.
PC4, through its interaction with p53 and by its inherent
DNA-bending ability, activates p53 function. Promoter-spe-
cific DNA binding by p53 is important for p53-mediated tran-
scriptional regulation, as well as its tumor suppressor function.
PC4 activates p53 DNA binding and, thereby, its transcrip-
tional regulatory functions. In order to investigate the in vivo
mechanisms of PC4-mediated activation of p53 recruitment,
p53-induced gene expression, and p53 downstream cellular
processes like apoptosis, we generated several mammalian ex-
pression clones of PC4 mutants. To further investigate the
effects of PC4 and its mutants in the recruitment of p53 to the
p53-responsive site in the Bax promoter in vivo, ChIP assays
FIG. 6. Acetylation of PC4 enhances its ability to activate p53 function. (A) PC4 was acetylated in vitro by p300 as described in Materials and
Methods, and the native PC4 and acetylated PC4 were analyzed on a 15% SDS-PAGE gel (panel I) and subjected to immunoblotting with
anti-acetylated-lysine antibodies (panel II). GST-p53 protein (panel III) was incubated with PC4 or acetylated PC4, and the interacting proteins
were monitored by immunoblotting with PC4 antibodies (panel IV). , anti. (B) PC4 was acetylated by p300 in vitro using cold acetyl-CoA as the
substrate, and the mock acetylation was done in the absence of acetyl-CoA. EMSA was performed with 50 ng of p53 either in the absence of PC4
(lane 2) or with increasing concentrations of PC4 (lanes 3 to 5), mock-acetylated PC4 (lanes 6 to 8), or acetylated PC4 (lanes 9 to 11). (C) The
levels of induction of p53-mediated binding are represented on the y axis, with increasing concentrations of PC4 or its acetylated form on the x
axis. Error bars show the standard errors of the means. (D) EMSA was performed with 50 ng of p53 in the absence of PC4 (lane 2), with increasing
concentrations of PC4 (lanes 3 and 4) or of acetylated PC4 in the absence of curcumin (lanes 5 and 6), or with acetylated PC4 in the presence of
curcumin (lane 7). (E) EMSAs were performed with 50 ng of p53 (lane 3) or 50 ng of acetylated p53 (lane 2). (F) EMSAs were performed with
50 ng of p53 either in the absence of PC4 (lane 2) or with increasing concentrations of PC4 (lanes 3 and 4) and with 50 ng of acetylated p53 either
in the absence of PC4 (lane 5) or with increasing concentrations of PC4 (lanes 6 and 7). Ac, acetylated; , present; , absent.
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were performed with H1299 cells transfected with p53 and
PC4/PC4 mutant mammalian constructs. Real-time PCR anal-
ysis was performed with primers specific to the p53-responsive
site in the Bax promoter. The results showed that the recruit-
ment of p53 to the Bax promoter is pronounced in the presence
of PC4 compared to recruitment with p53 alone (Fig. 9A and
B). PC4 1-87, PC4 22-127, PC4 40-127, PC4 62-127, and PC4
R70AY71A were able to activate p53 recruitment to the Bax
promoter in the presence of p53; however, PC4 1-62 and
PC462-87 activated p53 recruitment minimally and PC4 1-40
could not activate p53 recruitment (Fig. 9A and B). The effects
of PC4 truncation mutants on p53-mediated transactivation
were observed by performing transient transfections of PG13
Luc (contains 13 p53-responsive sites), p53, and PC4 or its
truncation mutants. The results showed that, in correlation
with the ChIP data, the PC4 truncation mutants PC4 1-62, PC4
1-87, PC4 22-127, and PC4 62-127 could activate p53-mediated
transactivation, with distinct abilities (data not shown). Similar
results were also seen when transfections were done with an
MDM2 Luc construct (data not shown). In order to find out
the correlation between p53 recruitment and p53-responsive
gene expression, H1299 cells were transfected with p53 in
combination with either PC4 or its mutants. Real-time PCR
analysis showed high levels of Bax mRNA and p21 mRNA
when p53 was cotransfected with PC4, PC4 1-87, PC4 22-127,
PC4 62-127, PC4 40-127, or PC4 R70AY71A in comparison to
the levels with p53 transfection alone (Fig. 9C and D and data
not shown). To investigate the downstream effect of p53-re-
sponsive proapoptotic gene expression, in a separate set of
similar experiments, cells were stained with Hoechst stain to
visualize the apoptotic nuclei and the percent apoptotic cells
was quantitated as described in Materials and Methods. Con-
sistent with the results of the real-time PCR analysis of Bax
gene expression, full-length PC4 could enhance p53-mediated
apoptosis. Interestingly, PC4 1-87, PC4 22-127, and PC4 62-
127 could also activate p53-mediated apoptosis at levels similar
to the level with full-length PC4 (Fig. 9E and F). However,
PC4 1-62 could activate p53-mediated Bax gene expression and
apoptosis only very minimally. In conclusion, the results sug-
gest that PC4 activates p53 recruitment to the p53-responsive
promoter through its interaction with p53 and by providing
bent substrate for p53 recruitment (Fig. 10). The activation
mechanism is further regulated by posttranslational modifica-
tions of PC4, as well as of p53.
DISCUSSION
The tumor suppressor p53 regulates the expression of sev-
eral genes involved in various cellular processes (11, 21, 31).
The activity of p53 is in turn regulated by several factors. A few
transcriptional coactivators play significant roles in p53 func-
tion via regulating its stability and transcriptional activity (2).
The highly abundant human transcriptional coactivator PC4
activates p53 function by enhancing p53 DNA binding and,
thereby, p53-responsive gene expression (4). Here we have
provided biochemical and cellular evidence revealing the mo-
lecular mechanisms of the PC4-mediated activation of p53
function. Our data suggest that three different molecular
mechanisms, namely, protein-protein (p53-PC4) interaction,
alteration of the secondary structure of DNA by PC4, and
posttranslational modifications (acetylation/phosphorylation)
of PC4, are involved in the activation of p53 function.
FIG. 7. PC4 is a DNA-bending protein. (A) The 5end -32P-labeled 123-bp DNA fragment (1 nM) was preincubated with different
concentrations of PC4 (0.05 M to 1.5 M), followed by ligation with 0.05 U of T4 DNA ligase at 30°C for 30 min. The reaction was stopped
using stop buffer, and the ligation products were subjected to electrophoresis on a 5% nondenaturing gel in 0.5 TBE buffer. The DNA
fragment (lane 1) was incubated in the presence of ligase (lane 2) or in the presence of ligase with increasing concentrations of PC4 (lanes
3 to 7). The sample was treated with exonuclease III after incubation with 1 M PC4 and ligase (lane 8). (B) Similar assays were performed
with increasing concentrations (0.05 M to 1.5 M) of PC4 1-62 (lanes 3 to 5), PC4 1-87 (lanes 7 to 9), PC4 22-127 (lanes 11 to 13), and
PC4 62-127 (lanes 15 to 17). Lanes 6, 10, 14, and 18 show the results for the samples treated with exonuclease III after incubation with 1
M PC4 1-62, PC4 1-87, PC4 22-127, and PC4 62-127, respectively, and ligase. L1, Linear monomer; L2, linear dimer. (C) Similar assays
were performed with increasing concentrations of PC462-87 (lanes 3 to 5). Lane 6 shows the results for the sample treated with exonuclease
III after incubation with 1 M PC462-87 and ligase. ExoIII, exonuclease III; , present; , absent.
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PC4 interacts with p53 at two distinct domains of p53, the
DNA binding domain and the highly flexible C-terminal reg-
ulatory domain. Surprisingly, we have found that the same
region in the DNA binding domain of PC4 mediates both the
interactions. Presumably, a multimeric form of PC4 (mostly
homodimer) could be interacting with p53. The detailed anal-
ysis of several truncation mutants of PC4 identified amino
acids 68 to 72 in PC4 as being responsible for the PC4-p53
interaction (Fig. 3B). Recent analysis of the cocrystal structure
of PC4 with 25-nucleotide single-strand DNA showed that this
region is present in a loop-	 sheet structure of the protein (42).
Interestingly, we found that PC4 62-127 does not interact with
p53 despite the presence of a p53-interacting region in it.
Presumably, the deletion of the N-terminal region could be
inhibiting the formation of the secondary structure that is re-
sponsible for p53 interaction (Fig. 1B, panel I). This assump-
tion is supported by our observation that phosphorylation of
PC4 abolishes the PC4-p53 interaction completely. PC4 is
phosphorylated by CKII on at least at 8 serine residues in the
N-terminal region, which presumably alters its structure (19).
Although the phosphorylation sites are not in the near vicinity
of the p53 interaction region, a structural alteration in PC4
upon phosphorylation could be acting as an inhibitory factor
for the PC4-p53 interaction. PC4 gets acetylated by p300 in
vitro and in vivo (26; K. Batta and T. K. Kundu, unpublished
data). Acetylation of PC4 does not alter the PC4-p53 interac-
tion but could induce the DNA binding ability of p53, suggest-
ing an alternate mechanism for the PC4-mediated activation of
p53 function, such as a PC4-induced alteration in DNA con-
formation. The identification of PC4 as a DNA-bending pro-
tein is a significant finding of this study. The more-efficient
binding of p53 to circular DNA than to linear DNA suggests a
role for PC4-mediated DNA bending in the enhanced DNA
binding of p53. As reported previously, HMGB1 also induces
p53 DNA binding by providing a bent surface for p53 recruit-
ment (30). DNA bending is known to be associated with tran-
scriptional activation, and p53 requires a bent DNA substrate
for its sequence-specific DNA binding (33, 43). The fact that
PC4 is a coactivator, DNA binding protein, as well as a p53-
interacting protein, indicates that PC4 binds and bends the
p53-responsive site, thereby allowing it to form a configuration
which shows high affinity for p53. The bending ability of PC4 is
further potentiated by p300-mediated acetylation. Mechanisti-
cally, this could be due to the higher affinity of acetylated PC4
for dsDNA (26). More-efficient bending by acetylated PC4
leads to the enhanced binding affinity of p53 for its consensus
sequence. Our study indicates that posttranslational modifica-
tions of the transcriptional coactivators also play a role in the
activation of p53 function.
The significant implications of these in vitro interaction and
DNA binding studies relate to the importance of transcrip-
tional activation in the p53 response. The ChIP assays and
real-time PCR analyses showed the in vivo recruitment of p53
to the Bax promoter and Bax mRNA levels in the presence of
various PC4 mutant constructs and p53. The results revealed
the importance of interaction (PC4 1-62) and DNA bending
(PC4 62-127) in the PC4-mediated activation of p53 function.
Although PC4 1-62 could not bend the DNA, it activated
p53-mediated gene expression with much lower efficiency than
the wild-type PC4 through its weak interaction with p53. This
weak interaction of PC4 1-62 and p53 could be further assisted
in vivo by endogenous PC4. It has been reported that inter- or
intramolecular interaction of the PC4 N-terminal domain with
the PC4 C-terminal domain regulates the interaction of PC4
with the transcriptional activator. Recent nuclear magnetic
resonance studies mapped the site of PC4 interaction with
VP16 to the C-terminal domain of PC4, but the N-terminal
domain of PC4 assists and enhances the interaction of the
C-terminal domain with VP16 (18). PC4 is a highly abundant
nuclear protein (
106 molecules per cell), so the overex-
pressed PC4 1-62 could interact with endogenous PC4 and
enhance its ability to interact with p53, thereby bringing about
the transcriptional activation mediated by p53. PC4 62-127,
FIG. 8. Acetylation of PC4 enhances its DNA-bending ability.
(A) Ligation-mediated circularization assays were performed with
increasing concentrations (0.05 M to 0.5 M) of PC4 (lanes 3 to
5) or acetylated PC4 (Ac-PC4) (lanes 7 to 9). Lanes 6 and 10 show
the results for the samples treated with exonuclease III after incu-
bation with PC4 and acetylated PC4, respectively, and ligase. Lane
1 shows the results for the DNA fragment, and lane 2 shows the
results for the DNA fragment in the presence of ligase. (B) Liga-
tion-mediated circularization assays were performed with increas-
ing concentrations (0.5 M to 1.5 M) of PC4 (lanes 3 to 5) or
phosphorylated PC4 (P-PC4) (lanes 7 to 9). Lanes 6 and 10 show
the results for the samples treated with exonuclease III after incu-
bation with PC4 and phosphorylated PC4, respectively, and ligase.
Lane 1 shows the results for the DNA fragment, and lane 2 shows
the results for the DNA fragment in the presence of ligase. ExoIII,
exonuclease III; , present; , absent.
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which did not show any interaction with p53, activated p53-
mediated gene expression, presumably by providing a bent
substrate for p53 recruitment. Homodimerization of PC4 is
linked to transcriptional activation. Overexpressed PC4 62-127
can dimerize with endogenous PC4 and, thus, can bring about
the activation of p53 function. Similarly, although PC4
R70AY71A showed very weak interaction with p53, it acti-
vated p53 function significantly, possibly through its dimeriza-
tion and DNA-bending abilities (data not shown).
However, PC4 is a very small multifunctional protein (127
amino acids) with several overlapping functional domains, so
naturally if any of the mutants shares (partially/completely)
any one of these functions, that could result in the activation of
p53 function. The PC4 1-62, PC462-87, and PC4 1-40 mutants
showed very weak/no interaction with p53, could not bend the
DNA, and, as expected, could only very minimally activate
p53 function (p53 recruitment and p53-mediated endoge-
nous gene expression) in vivo compared to the effect of the
full-length protein (Fig. 9). Furthermore, although PC4 62-
127 and PC4 R70AY71A showed no/very weak interaction
with p53, because of their DNA-bending ability they acti-
vated p53 function substantially in vivo. These results high-
light the importance of the DNA-bending property of PC4
in activating p53 function.
It would be interesting to find out the specificity of PC4-
mediated coactivation in different cell types and classes of
promoter. p53, a sequence-specific transcriptional activator
(quite often acting as a repressor) binds to the cognate sites
and recruits histone acetyltransferases p300/CBP. Possibly
through protein-protein interaction, PC4 is also recruited to
the cognate sites and is acetylated by p300/CBP. The en-
hanced binding of p53 in the presence of acetylated PC4
could lead to the activation of downstream processes, such
as apoptosis. Therefore, the PC4-mediated activation of p53
function may be responsible for global regulation of cellular
function.
FIG. 9. PC4 activates p53-mediated apoptosis by recruiting p53 to the Bax promoter. (A and B) H1299 cells were transfected with p53
(2.5 g) and PC4 or its truncation mutants (5 g) in combinations as indicated below the histograms. ChIP assays were performed using p53
antibody or control immunoglobulin G (IgG) and specific primers for the p53-responsive site in the Bax promoter. (C and D) H1299 cells
were transfected with p53 (2.5 g) alone or in combination with PC4 or its mutants (5 g). RNA was isolated, and real-time PCR analysis
was done using gene-specific primers for Bax, with 	-actin as a control. (E) H1299 cells were transfected with p53 (2.5 g) alone or in
combination with PC4 or its truncation mutants (5 g). The cells were stained with Hoechst stain after 24 h of transfection and visualized
under a fluorescence microscope. Apoptotic nuclei are shown with arrowheads. (F) The average percent apoptotic nuclei was plotted on the
y axis against each combination of plasmids transfected, indicated below the histogram. Error bars show the standard errors of the means.
, present; , absent.
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Several reports postulate PC4 as a putative tumor suppres-
sor, and our results strengthen this concept. According to the
results of our study, PC4 gene expression is also regulated
by p53 (22) and is induced upon genotoxic insult. We have
also shown that PC4 activates p53-mediated apoptosis, sug-
gesting the role of PC4 as a tumor suppressor. Given the
multiple roles of PC4 in various cellular processes, it will be
interesting to generate a mouse knockout model to further
investigate its physiological role. However, the present find-
ings may establish general mechanisms of p53 activation by
highly abundant coactivators under the guidance of different
cellular signals.
ACKNOWLEDGMENTS
We thank the Department of Science and Technology and the De-
partment of Biotechnology of the government of India and JNCASR
for financial support. K.B. is a CSIR senior research fellow.
We gratefully acknowledge K. K. Febita, Hari Kishore, Saurav Ban-
erjee, and Swaminathan Venkatesh for the valuable reagents and help-
ful suggestions they provided.
REFERENCES
1. An, W., J. Kim, and R. G. Roeder. 2004. Ordered cooperative functions of
PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117:
735–748.
2. Ashcroft, M., and K. H. Vousden. 1999. Regulation of p53 stability. Onco-
gene 18:7637–7643.
3. Balasubramanyam, K., R. A. Varier, M. Altaf, V. Swaminathan, N. B.
Siddappa, U. Ranga, and T. K. Kundu. 2004. Curcumin, a novel p300/
CREB-binding protein-specific inhibitor of acetyltransferase, represses the
acetylation of histone/nonhistone proteins and histone acetyltransferase-
dependent chromatin transcription. J. Biol. Chem. 279:51163–51171.
4. Banerjee, S., B. R. Kumar, and T. K. Kundu. 2004. General transcriptional
coactivator PC4 activates p53 function. Mol. Cell. Biol. 24:2052–2062.
5. Buschmann, T., Y. Lin, N. Aithmitti, S. Y. Fuchs, H. Lu, L. Resnick-Silverman,
J. J. Manfredi, Z. Ronai, and X. Wu. 2001. Stabilization and activation of p53 by
the coactivator protein TAFII31. J. Biol. Chem. 276:13852–13857.
6. Chen, X., G. Farmer, H. Zhu, R. Prywes, and C. Prives. 1993. Cooperative
DNA binding of p53 with TFIID (TBP): a possible mechanism for transcrip-
tional activation. Genes Dev. 7:1837–1849.
7. Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumu-
lation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol.
Cell. Biol. 14:1997–2003.
8. Chuikov, S., J. K. Kurash, J. R. Wilson, B. Xiao, N. Justin, G. S. Ivanov, K.
McKinney, P. Tempst, C. Prives, S. J. Gamblin, N. A. Barlev, and D. Rein-
berg. 2004. Regulation of p53 activity through lysine methylation. Nature
432:353–360.
9. Das, C., K. Hizume, K. Batta, B. R. P. Kumar, S. S. Gadad, S. Ganguly, S.
Lorain, A. Verreault, P. P. Sadhale, K. Takeyasu, and T. K. Kundu. 2006.
Transcriptional coactivator PC4, a chromatin-associated protein, induces
chromatin condensation. Mol. Cell. Biol. 26:8303–8315.
10. Dornan, D., I. Wertz, H. Shimizu, D. Arnott, D. G. Frantz, P. Dowd, K.
O’Rourke, H. Koeppen, and V. M. Dixit. 2004. The ubiquitin ligase COP1 is
a critical negative regulator of p53. Nature 429:86–92.
11. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M.
Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1,
a potential mediator of p53 tumor suppression. Cell 75:817–825.
12. Ge, H., and R. G. Roeder. 1994. Purification, cloning, and characterization of
a human coactivator, PC4, that mediates transcriptional activation of class II
genes. Cell 78:513–523.
13. Ge, H., Y. Zhao, B. T. Chait, and R. G. Roeder. 1994. Phosphorylation
negatively regulates the function of coactivator PC4. Proc. Natl. Acad. Sci.
USA 91:12691–12695.
14. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA
binding by acetylation of the p53 C-terminal domain. Cell 90:595–606.
15. Haupt, Y., R. Maya, A. Kaza, and M. Oren. 1997. Mdm2 promotes the rapid
degradation of p53. Nature 387:296–299.
16. Huang, Q., A. Raya, P. DeJesus, S. H. Chao, K. C. Quon, J. S. Caldwell, S. K.
Chanda, J. C. Izpisua-Belmonte, and P. G. Schultz. 2004. Identification of
p53 regulators by genome-wide functional analysis. Proc. Natl. Acad. Sci.
USA 101:3456–3461.
17. Jayaraman, L., N. C. Moorthy, K. G. Murthy, J. L. Manley, M. Bustin, and
C. Prives. 1998. High mobility group protein-1 (HMG-1) is a unique activa-
tor of p53. Genes Dev. 12:462–472.
18. Jonker, H. R., R. W. Wechselberger, R. Boelens, R. Kaptein, and G. E.
Folkers. 2006. The intrinsically unstructured domain of PC4 modulates the
activity of the structured core through inter- and intramolecular interactions.
Biochemistry 45:5067–5081.
19. Jonker, H. R., R. W. Wechselberger, M. Pinkse, R. Kaptein, and G. E.
Folkers. 2006. Gradual phosphorylation regulates PC4 coactivator function.
FEBS J. 273:1430–1444.
20. Kannan, P., and M. A. Tainsky. 1999. Coactivator PC4 mediates AP-2
transcriptional activity and suppresses ras-induced transformation depen-
dent on AP-2 transcriptional interference. Mol. Cell. Biol. 19:899–908.
21. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh,
B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian
cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in
ataxia-telangiectasia. Cell 71:587–597.
22. Kishore, A. H., K. Batta, C. Das, S. Agarwal, and T. K. Kundu. 8 June 2007.
p53 regulates its own activator: transcriptional co-activator PC4, a new p53-
responsive gene. Biochem. J. doi:10.1042/BJ20070390.
23. Knights, C. D., J. Catania, S. D. Giovanni, S. Muratoglu, R. Perez, A.
Swartzbeck, A. A. Quong, X. Zhang, T. Beerman, R. G. Pestell, and M. L.
Avantaggiati. 2006. Distinct p53 acetylation cassettes differentially influence
gene-expression patterns and cell fate. J. Cell Biol. 173:533–544.
24. Ko, L. J., and C. Prives. 1996. p52: puzzle and paradigm. Genes Dev.
10:1054–1072.
25. Kubbutat, M. H. G., S. N. Jones, and K. Vousden. 1997. Regulation of p53
stability by MDM2. Nature 387:299–303.
26. Kumar, B. R., V. Swaminathan, S. Banerjee, and T. K. Kundu. 2001. p300-
mediated acetylation of human transcriptional coactivator PC4 is inhibited
by phosphorylation. J. Biol. Chem. 276:16804–16809.
27. Kundu, T. K., Z. Wang, and R. G. Roeder. 1999. Human TFIIIC relieves
chromatin-mediated repression of RNA polymerase III transcription and
contains an intrinsic histone acetyltransferase activity. Mol. Cell. Biol. 19:
1605–1615.
28. Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G.
Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-
protein ligase, promotes p53 degradation. Cell 112:779–791.
29. Li, M., C. L. Brooks, N. Kon, and W. Gu. 2004. A dynamic role of HAUSP
in the p53-Mdm2 pathway. Mol. Cell 13:879–886.
30. McKinney, K., and C. Prives. 2002. Efficient specific DNA binding by p53
requires both its central and C-terminal domains as revealed by studies with
high-mobility group 1 protein. Mol. Cell. Biol. 22:6797–6808.
31. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct
transcriptional activator of the human bax gene. Cell 80:293–299.
32. Mosner, J., T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, and W.
Deppert. 1995. Negative feedback regulation of wild-type p53 biosynthesis.
EMBO J. 14:4442–4449.
33. Nagaich, A. K., E. Appella, and R. E. Harrington. 1997. DNA bending is
essential for the site-specific recognition of DNA response elements by the
DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem.
272:14842–14849.
34. Oliner, J. D., J. A. Pientenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler,
FIG. 10. PC4 activates p53 function through its interaction with
and recruitment of p53 and by providing bent substrate for efficient
binding of p53 to its cognate sites.
VOL. 27, 2007 MECHANISMS OF ACTIVATION OF p53 FUNCTION BY PC4 7613
and B. Vogelstein. 1993. Oncoprotien MDM2 conceals the activation domain
of tumor suppressor p53. Nature 362:857–860.
35. Pan, Z. Q., H. Ge, A. A. Amin, and J. Hurwitz. 1996. Transcription-positive
cofactor 4 forms complexes with HSSB (RPA) on single-stranded DNA and
influences HSSB dependent enzymatic synthesis of simian virus 40 DNA.
J. Biol. Chem. 271:22111–22116.
36. Pokholok, D. K., C. T. Harbison, S. Levine, M. Cole, N. M. Hannett, G. W.
Bell, K. Walker, P. A. Rolfe, E. Herbolsheimer, J. Zeitlinger, F. Lewitter,
D. K. Gifford, and R. A. Young. 2005. Genome-wide map of nucleosome
acetylation and methylation in yeast. Cell 122:517–527.
37. Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Allan, L.
Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A.
DePinho. 1998. The Ink4a tumor suppressor gene product, p19ARF, inter-
acts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723.
38. Samuels-Lev, Y., D. J. O’Connor, D. Bergamaschi, G. Trigiante, J. K. Hsieh, S.
Zhong, I. Campargue, L. Naumovski, T. Crook, and X. Lu. 2001. ASPP proteins
specifically stimulate the apoptotic function of p53. Mol. Cell 8:781–794.
39. Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced
phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325–334.
40. Stros, M. 1998. DNA bending by the chromosomal protein HMG1 and its
high mobility group box domains. Effect of flanking sequences. J. Biol.
Chem. 273:10355–10361.
41. Wang, J. Y., A. H. Sarker, P. K. Cooper, and M. R. Volkert. 2004. The
single-strand DNA binding activity of human PC4 prevents mutagenesis and
killing by oxidative DNA damage. Mol. Cell. Biol. 24:6084–6093.
42. Werten, S., and D. Moras. 2006. A global transcription cofactor bound to
juxtaposed strands of unwound DNA. Nat. Struct. Mol. Biol. 13:181–182.
43. Wu, J., K. M. Parkhurst, R. M. Powell, and L. J. Parkhurst. 2001. DNA
sequence-dependent differences in TATA-binding protein-induced DNA
bending in solution are highly sensitive to osmolytes. J. Biol. Chem. 276:
14623–14627.
7614 BATTA AND KUNDU MOL. CELL. BIOL.
